trending Market Intelligence /marketintelligence/en/news-insights/trending/c863tjzo98jpth-vnhpf2a2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Arcus Biosciences plans $100M IPO


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective

Arcus Biosciences plans $100M IPO

Arcus Biosciences Inc. plans to offer up to $100 million of its common shares in an IPO.

The clinical-stage biopharmaceutical company focused on creating cancer immunotherapies has applied to list its common stock on the New York Stock Exchange under the symbol RCUS.

Arcus plans to use the net proceeds to fund the clinical development of its product candidates, drug discovery and optimization programs as well as other general corporate purposes.

Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Leerink Partners LLC are acting as joint book-running managers of the offering.